Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01113801 · ClinicalTrials.gov registry record · Phase 2
A Study in Participants With Diabetic Kidney Disease
A Phase 2 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 417
- Enrollment target
NCT01113801 is a Phase 2 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 417 participants.
The verdict
NCT01113801, a Phase 2 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 417 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if LY2382770 is safe and effective at protecting kidney function in participants with kidney disease due to diabetes.
Interventions
- DRUG Placebo
- DRUG LY2382770
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 417 participants |
| Start Date | 2010-07 |
| Est. Completion | 2014-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01113801
The ClinicalTrials.gov registry entry for NCT01113801 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 417 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01113801 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01113801 about?
NCT01113801 is a clinical study titled "A Study in Participants With Diabetic Kidney Disease". The purpose of this study is to determine if LY2382770 is safe and effective at protecting kidney function in participants with kidney disease due to diabetes.
What is the current status of trial NCT01113801?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 417 participants. The study started on 2010-07. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01113801?
The interventions under investigation include: Placebo (DRUG), LY2382770 (DRUG).
Who is sponsoring clinical trial NCT01113801?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.